原发性前列腺恶性淋巴瘤11例诊治报道  

Diagnoses and Treatment Reports of 11 Cases of Primary Malignant Lymphoma of Prostate

作　　者：陈征[1] 李馨[2] 王珏[3] 潘宇航[4] 梁琼[4] 邵春奎[4] 高新[1] 庞俊[1] Chen Zheng Li Xin Wang Jue Pan Yuhang Liang Qiong Shao Chunkuia Gao Xin Pang Jun(Department of Urology, The Third Affiliated Hospital, Sun Yat - sen University, Guangzhou, 510630 , Guangdong , China Affiliated hospital of Pingdingshan College, Pingdingshan , 467000 ,Henan, China Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080 , Guangdong, China Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou , 510630 , Guangdong , China)

机构地区：[1]中山大学附属第三医院泌尿外科,广州510630 [2]平顶山学院,河南平顶山467000 [3]中山大学附属第一医院病理科,广州510080 [4]中山大学附属第三医院病理科,广州510630

出　　处：《肿瘤预防与治疗》2017年第2期102-106,120,共6页Journal of Cancer Control And Treatment

基　　金：广州市科技计划项目(编号201604020006)

摘　　要：目的:探讨原发性前列腺恶性淋巴瘤(primary malignant lymphoma of the prostate,PMLP)的临床诊治特征及预后。方法:收集中山大学附属第三医院、中山大学附属第一医院、平顶山学院附属医院2005年11月至2016年12月共11例PMLP患者的临床资料、诊疗及预后信息。结果:11例患者发病年龄57~82岁,中位年龄68岁。血清前列腺特异性抗原(prostate-specific antigen,PSA)平均2.68ng/ml(0.54~4.82ng/ml),血清乳酸脱氢酶(LDH)平均值为314.9(123~560)U/L。CT检查均提示前列腺明显增大,临床下尿路梗阻症状明显。组织病理学符合B细胞源性非霍奇金淋巴瘤,其中弥漫大B淋巴瘤9例,套细胞淋巴瘤2例。中位生存期28个月(9~62月),6例已死亡。10例选择手术治疗,6例术后进一步接受CHOP或R-CHOP化疗,其中3例生存期已超过56个月。结论:PMLP罕见,预后与病理组织学分类、临床分期及治疗方案紧密相关。实验室检查(PSA、LDH)、CT检查特异性不明显。PMLP化疗效果明显,手术可有效缓解下尿路梗阻症状,必要时可联合治疗。Objective： To investigate the clinical features and prognosis of primary malignant lymphoma of the prostate （PMLP）. Methods： From November 2005 to December 2016, clinical, diagnose and pathologic data of eleven patients from the Third Affiliated Hospital of Sun Yat-sen University, the First Affiliated Hospital of Sun Yat-sen University and the Affiliated Hospital of Pingdingshan University were collected for analysis. Results： Lymphoma tended to occur in an elderly patient, with a mean age at diagnosis of 68 years （ range ： 57 - 82 years）. The average serum prostate-specific antigen（PSA） levels and lactate dehydrogenase （LDH） levels were 2.68ng/ml （range： 0.54 -4.82ng/ml） and 314.9 U/L（ 123.0 - 560.0 U/L）, respectively. Computed tomography （CT） imaging demonstrated a large mass in the prostate, as well as obvious low urinary tract symptoms （LUTS） resulting from infiltration of the mass. Histological findings revealed diffuse large B-cell non-Hodgkin＇s lymphoma, including nine cases with diffuse large B-cell lymphoma and two cases of mantle cell lymphoma. The median survival time was 28 months, （ range ： 9 ~ 62 months）, with six patients died of malig-nant lympboma. Of them, 10 patients underwent surgery, 6 of them underwent subsequent CHOP or R-CHOP chemotherapy and 50% （3 of 6） displayed a survival time over 56 months. Conclusion： PMLP is a rare prostatic malignancy involving the prostate, which displayed few specific characteristic signs on laboratory tests （i. e. PSA and LDH） and CT examination. However, patients with PMLP respond well to chemotherapy, and combined treatment with operative intervention should be taken into account as LUTS could be cured by surgery.

关 键 词：淋巴瘤 前列腺 诊断 治疗 

分 类 号：R737.25[医药卫生—肿瘤]